Syntis Bio reports SYNT-101 Phase 1/1b results showing up to 2.30% placebo-adjusted weight change and satiety hormone responses after 28 days.
Written By: Faiza, PharmD
Reviewed By: Pharmacally Editorial Team
Syntis Bio, Inc. reported late-breaking results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily oral therapy for obesity, at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026 in Washington, DC. The findings provide preliminary evidence of weight change and hormonal activity with the company’s intestinal nutrient-redirection approach.
SYNTIETY-1 Trial Design
The randomized, double-blind, placebo-controlled Phase 1/1b trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of SYNT-101 through two study portions:
- Single ascending dose (SAD): 32 healthy adults with BMI 18.5–29.9 kg/m² received single doses ranging from 857 mg to 3,428 mg across four cohorts or placebo.
- Multiple ascending dose (MAD): 23 adults with obesity (BMI 30 to less than 40 kg/m²) received 857 mg, 1,714 mg or 2,571 mg once daily for 28 days across three dose cohorts or placebo.
The MAD doses corresponded to one, two and three tablets, respectively, while the highest SAD dose required four tablets. Exact participant allocation across the MAD arms was not disclosed in the November announcement.
How SYNT-101 Works
SYNT-101 uses Syntis Bio’s SYNT™ (SYNthetic Tissue-lining) technology, a mussel-inspired polymer platform designed to form a transient polydopamine coating on catalase-rich tissues such as the duodenum.
Catalase-mediated breakdown of hydrogen peroxide generates oxygen, supporting dopamine oxidation and polymerization at the intestinal surface. The resulting lining is designed to persist for up to 24 hours before being naturally cleared.
The approach aims to temporarily limit nutrient absorption in the proximal small intestine and redirect nutrients towards the distal intestine, stimulating endogenous satiety hormones rather than directly activating a single receptor. The company designed the therapy to act locally within the gastrointestinal tract without systemic absorption.
Earlier SAD Findings
Initial SAD results announced in July 2026 provided preliminary evidence of pharmacodynamic activity. The company reported a 17% reduction in glucose absorption during OGTT monitoring compared with baseline.
At the single-tablet dose, reported hormonal changes included a 58% increase in total GLP-1, a 125% increase in peptide YY (PYY), a 21% reduction in ghrelin and a 100% increase in leptin. These findings supported further evaluation in the multiple-dose portion.
MAD Results: Weight Change and Hormonal Response
The latest MAD results presented at ObesityWeek showed the following placebo-adjusted weight changes at Day 28:
Daily dose | Placebo-adjusted change |
857 mg | −1.26% |
1,714 mg | −0.46% |
2,571 mg | −2.30% |
Pooled | −1.37% |
The pooled result had a nominal p-value of 0.007.
Hormonal assessments at Day 28 showed a 5.1-fold increase in PYY and a 2.3-fold increase in GLP-1 responses compared with pretreatment levels, alongside 37% suppression of ghrelin and no reported change in insulin. The highest-dose cohort showed the largest PYY response, at 8.7-fold, and the greatest cohort-level weight reduction.
The intermediate-dose cohort showed a smaller weight change than the lowest-dose cohort, indicating no consistent dose-response relationship. The company also described a broader hormonal signature involving GLP-1, PYY, ghrelin and GIP, resembling aspects of the hormonal response associated with gastric bypass surgery.
Safety and Tolerability
Across the SAD and MAD portions, no discontinuations were reported among 55 dosed participants. No dose reductions were reported in the MAD cohorts. Treatment-related gastrointestinal adverse events occurred in 35% of SYNT-101 recipients versus 33% of placebo recipients, without an apparent dose-response pattern. No treatment-related vomiting was reported.
The July SAD readout also reported mild, self-limited hypoglycemia during OGTT as a treatment-related adverse event.
Separately, preclinical rodent studies reported approximately 1% weekly weight loss with 100% preservation of lean muscle mass. This finding has not been established in humans.
Phase 2 Development Plans
Syntis Bio plans to initiate a Phase 2 study in 2027 to assess dose response and weight-loss trajectories over a longer treatment period. The company is also exploring potential applications in combination with GLP-1 therapies and as a maintenance approach following GLP-1 discontinuation. These remain proposed development opportunities rather than established clinical uses.
The company is also investigating broader SYNT platform applications, including enhancing oral peptide bioavailability and retaining therapeutic enzymes for rare paediatric metabolic diseases.
Clinical Interpretation and Limitations
SYNTIETY-1 provides early clinical evidence of hormonal activity and a preliminary weight-change signal with an oral nutrient-redirection approach. However, the MAD portion included only 23 participants with obesity and lasted 28 days. Weight and hormonal outcomes were exploratory, and the pooled p-value was nominal, without reported adjustment for multiple comparisons.
The November announcement did not provide baseline mean body weight, absolute weight changes in kilograms, placebo-arm weight change or exact participant allocation by dose. These omissions limit interpretation of the magnitude and consistency of the observed weight changes.
Longer-term efficacy, durability of hormone modulation, effects on metabolic comorbidities, human lean-mass preservation and chronic gastrointestinal safety remain unknown. The findings do not establish equivalence to bariatric surgery or approved obesity treatments.
SYNT-101 remains investigational and is not approved by any regulatory authority. The planned Phase 2 programme will be important in determining whether these early findings translate into sustained clinical benefit.
References
Syntis Bio Reports Late-Breaking SYNTIETY-1 Data at ObesityWeek® 2026 Demonstrating Daily Oral SYNT-101 Mimics Gastric Bypass Hormone Response with Placebo-Like Tolerability, Syntix Bio, 16 November 2026
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults, ClinicalTrials.gov ID NCT07307274
About the Writer
Faiza (Linkedin) is a Healthcare Writer at Pharmacally and a PharmD professional from St. Peter’s Institute of Pharmaceutical Sciences, Kakatiya University. she has academic and clinical interests in clinical pharmacy, pharmacovigilance and patient care. Her research focuses on serum biomarkers in acute pancreatitis and medication adherence. She is interested in clinical research, medical writing and evidence-based healthcare communication.
